{
    "clinical_study": {
        "@rank": "127830", 
        "arm_group": [
            {
                "arm_group_label": "BOTOX\u00ae 24U", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum Toxin Type A (BOTOX\u00ae) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable."
            }, 
            {
                "arm_group_label": "BOTOX\u00ae 48U", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum Toxin Type A (BOTOX\u00ae) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable."
            }, 
            {
                "arm_group_label": "BOTOX\u00ae 72U", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum Toxin Type A (BOTOX\u00ae) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable."
            }, 
            {
                "arm_group_label": "BOTOX\u00ae 96U", 
                "arm_group_type": "Active Comparator", 
                "description": "Botulinum Toxin Type A (BOTOX\u00ae) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type\n      A (BOTOX\u00ae) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH)."
        }, 
        "brief_title": "Botulinum Toxin Type A (BOTOX\u00ae) Treatment of Masseter Muscle Hypertrophy", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Masticatory Muscles, Hypertrophy of", 
        "condition_browse": {
            "mesh_term": "Hypertrophy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants with Masseter Muscle Hypertrophy Exclusion Criteria:\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral\n             sclerosis, or any other condition that might interfere with neuromuscular function\n\n          -  Prior botulinum toxin treatment of any serotype to the masseter muscle or lower face\n\n          -  History of dental or surgical procedure for lower facial shaping or masseter muscle\n             reduction\n\n          -  History of or current temporomandibular joint disorder (TMJD) or Class III\n             malocclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010775", 
            "org_study_id": "191622-130"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BOTOX\u00ae 24U", 
                    "BOTOX\u00ae 48U", 
                    "BOTOX\u00ae 72U", 
                    "BOTOX\u00ae 96U"
                ], 
                "description": "Botulinum toxin Type A (BOTOX\u00ae) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.", 
                "intervention_name": "botulinum toxin Type A", 
                "intervention_type": "Biological", 
                "other_name": "BOTOX\u00ae"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 28, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Vancouver", 
                    "country": "Canada", 
                    "state": "British Columbia"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "5", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Lower Facial Volume Calculated by Digital Imaging", 
            "safety_issue": "No", 
            "time_frame": "Day 90"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Investigator's Assessment of Masseter Muscle Hypertrophy (MMH) using a 5-Point Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 90"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}